ENVB
ENVB
NASDAQ · Pharmaceuticals

Enveric Biosciences Inc

$1.95
-0.05 (-2.50%)
As of Mar 24, 10:15 PM ET ·
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +408.2% upside
Low Target $5.56
Average Target $9.91
High Target $13.09
Current Price $1.95
Current
$1.95
Target
$9.91
$5.56 $9.91 avg $13.09
Scenario Analysis
Bear Case
$5.56
185.1%
Low target
Base Case
$9.91
+408.2%
Avg target
Bull Case
$13.09
+571.3%
High target
Risk/Reward
3.1x
Highly favorable
Price in Context
52-Week High
$21.60
-91.0% from high
52-Week Low
$1.82
+7.1% from low
Target vs 52W High
$9.91
-54.1% vs high
Next Earnings Report
Mar 26, 2026 · After Market Close
Today
EPS Est: $-0.32
Earnings in today. Analyst targets may shift significantly after the report.
Peer Consensus — Pharmaceuticals
Stock Consensus Analysts Buy % Target Upside
LLY
Eli Lilly and Co.
Strong Buy 39 77% $1,330.33 +45.2%
JNJ
Johnson & Johnson
Buy 32 59% $299.55 +24.8%
MRK
Merck & Co. Inc.
Buy 36 67% $159.27 +33.4%
PFE
Pfizer Inc.
Hold 35 40% $33.90 +24.3%
BMY
Bristol-Myers Squibb Co
Hold 36 42% $174.50 +196.1%
ZTS
Zoetis Inc
Buy 25 64% $209.87 +79.8%
RPRX
Royalty Pharma Plc- Cl A
Strong Buy 16 88% $36.26 -22.9%
VTRS
Viatris Inc
Buy 18 67% $122.82 +809.8%